<DOC>
	<DOC>NCT00694187</DOC>
	<brief_summary>The objective of this study was to show the bioequivalence of a Roxane Laboratories' Zaleplon Capsules, 10 mg, to Sonata Â® Capsules, 10 mg (Jones Pharma) under fasting conditions using a single-dose, randomized, 2-treatment, 2-period, 2-sequence crossover design</brief_summary>
	<brief_title>Bioequivalency Study of Zaleplon 10 mg Capsules Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Zaleplon</mesh_term>
	<criteria>No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening. Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to Zaleplon or any comparable or similar product.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>